{"id":53795,"date":"2026-01-12T22:09:57","date_gmt":"2026-01-12T14:09:57","guid":{"rendered":"https:\/\/flcube.com\/?p=53795"},"modified":"2026-01-12T22:09:58","modified_gmt":"2026-01-12T14:09:58","slug":"santens-upneeq-wins-japan-approval-for-acquired-ptosis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53795","title":{"rendered":"Santen&#8217;s UPNEEQ Wins Japan Approval for Acquired Ptosis"},"content":{"rendered":"\n<p><strong>Santen Pharmaceutical Co., Ltd.<\/strong> announced that <strong>UPNEEQ Mini 0.1% oxymetazoline solution (STN1013800)<\/strong> has been approved in Japan for the treatment of <strong>acquired ptosis<\/strong>, becoming the <strong>first non\u2011invasive therapy<\/strong> for the condition in the country. The approval marks a significant advancement in ptosis management, offering an alternative to surgical intervention for a broad patient population.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-amp-regulatory-milestone\">Product &amp; Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>UPNEEQ Mini 0.1% oxymetazoline solution (STN1013800)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Santen Pharmaceutical Co., Ltd. (Japan)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Approved in Japan for acquired ptosis<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>\u03b1\u2011receptor agonist acting on M\u00fcller\u2019s muscle, causing contraction to lift upper eyelid<\/td><\/tr><tr><td><strong>Clinical Data<\/strong><\/td><td>Phase\u202fIII trial showed significant MRD\u20111 improvement vs. placebo at 2 hours post\u2011administration<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Overall favorable, with no major safety concerns<\/td><\/tr><tr><td><strong>Market Significance<\/strong><\/td><td>First non\u2011invasive therapy approved for ptosis in Japan<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-mechanism-of-action\">Market Opportunity &amp; Mechanism of Action<\/h2>\n\n\n\n<p><strong>Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ptosis Prevalence<\/strong>: <strong>~200,000\u2011300,000<\/strong> patients in Japan with acquired ptosis<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: <strong>Surgical intervention<\/strong> is primary treatment, posing risks and costs<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: <strong>Non\u2011invasive alternative<\/strong> for patients seeking aesthetic or functional improvement without surgery<\/li>\n<\/ul>\n\n\n\n<p><strong>Mechanism<\/strong>:<br>UPNEEQ Mini\u2019s active ingredient, <strong>oxymetazoline<\/strong>, selectively activates <strong>\u03b1\u2011adrenergic receptors<\/strong> in <strong>M\u00fcller\u2019s muscle<\/strong>, a key muscle in eyelid elevation. This induces <strong>muscle contraction<\/strong>, lifting the upper eyelid within <strong>2 hours<\/strong> of administration.<\/p>\n\n\n\n<p><strong>Clinical Efficacy<\/strong>:<br>Phase\u202fIII trials demonstrated <strong>statistically significant improvement<\/strong> in <strong>Marginal Reflex Distance\u20111 (MRD\u20111)<\/strong>, the distance between the upper eyelid margin and pupil center, confirming therapeutic benefit.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-licensing-amp-commercial-rights\">Licensing &amp; Commercial Rights<\/h2>\n\n\n\n<p><strong>Strategic Partnership<\/strong>:<br>Santen entered into an <strong>exclusive licensing agreement<\/strong> with <strong>Osmotica Pharmaceuticals plc<\/strong> (renamed <strong>RVL Pharmaceuticals, Inc.<\/strong>) in <strong>July\u202f2020<\/strong>, securing rights for <strong>development, registration, and commercialization<\/strong> in <strong>Japan, China, other Asian countries, and EMEA<\/strong>.<\/p>\n\n\n\n<p><strong>Geographic Scope<\/strong>: The approval in Japan paves the way for <strong>regulatory submissions in China and other Asian markets<\/strong>, leveraging the same clinical data package.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Treatment<\/th><th>Company<\/th><th>Approach<\/th><th>Japan Status<\/th><th>Key Limitations<\/th><\/tr><\/thead><tbody><tr><td><strong>Surgery<\/strong><\/td><td>Various<\/td><td>Invasive<\/td><td>Standard of care<\/td><td>Cost, recovery time, complications<\/td><\/tr><tr><td><strong>UPNEEQ Mini<\/strong><\/td><td><strong>Santen<\/strong><\/td><td>Non\u2011invasive (eye drops)<\/td><td><strong>Approved<\/strong><\/td><td><strong>First non\u2011invasive option<\/strong><\/td><\/tr><tr><td><strong>Other pharmacologic<\/strong><\/td><td>None<\/td><td>\u2013<\/td><td>Not approved<\/td><td>Limited efficacy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>First\u2011Mover Advantage<\/strong>: Santen captures <strong>premium pricing<\/strong> in a <strong>previously untapped<\/strong> non\u2011invasive segment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<p><strong>Market Opportunity<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Japan Market Size<\/strong>: <strong>\u00a515\u201120\u202fbillion<\/strong> (US$130\u2011175\u202fmillion) peak potential by 2030<\/li>\n\n\n\n<li><strong>Pricing<\/strong>: Projected <strong>\u00a58,000\u201110,000<\/strong> monthly (vs. <strong>\u00a5150,000\u2011200,000<\/strong> for surgery)<\/li>\n\n\n\n<li><strong>Peak Penetration<\/strong>: <strong>30\u201140%<\/strong> of eligible patients<\/li>\n<\/ul>\n\n\n\n<p><strong>Licensing Economics<\/strong>: Royalties to <strong>RVL Pharmaceuticals<\/strong> are expected to be <strong>mid\u2011single digit<\/strong> on net sales, with Santen retaining <strong>majority of profits<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding UPNEEQ Mini\u2019s market penetration, revenue forecasts, and regulatory submissions in other Asian markets. Actual results may differ materially due to competitive dynamics, pricing negotiations, and reimbursement policies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Santen Pharmaceutical Co., Ltd. announced that UPNEEQ Mini 0.1% oxymetazoline solution (STN1013800) has been approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[44,15,415],"class_list":["post-53795","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ophthalmology","tag-product-approvals","tag-santen-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Santen&#039;s UPNEEQ Wins Japan Approval for Acquired Ptosis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Santen Pharmaceutical Co., Ltd. announced that UPNEEQ Mini 0.1% oxymetazoline solution (STN1013800) has been approved in Japan for the treatment of acquired ptosis, becoming the first non\u2011invasive therapy for the condition in the country. The approval marks a significant advancement in ptosis management, offering an alternative to surgical intervention for a broad patient population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53795\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Santen&#039;s UPNEEQ Wins Japan Approval for Acquired Ptosis\" \/>\n<meta property=\"og:description\" content=\"Santen Pharmaceutical Co., Ltd. announced that UPNEEQ Mini 0.1% oxymetazoline solution (STN1013800) has been approved in Japan for the treatment of acquired ptosis, becoming the first non\u2011invasive therapy for the condition in the country. The approval marks a significant advancement in ptosis management, offering an alternative to surgical intervention for a broad patient population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53795\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T14:09:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T14:09:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53795#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53795\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Santen&#8217;s UPNEEQ Wins Japan Approval for Acquired Ptosis\",\"datePublished\":\"2026-01-12T14:09:57+00:00\",\"dateModified\":\"2026-01-12T14:09:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53795\"},\"wordCount\":443,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ophthalmology\",\"Product approvals\",\"Santen Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53795#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53795\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53795\",\"name\":\"Santen's UPNEEQ Wins Japan Approval for Acquired Ptosis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-12T14:09:57+00:00\",\"dateModified\":\"2026-01-12T14:09:58+00:00\",\"description\":\"Santen Pharmaceutical Co., Ltd. announced that UPNEEQ Mini 0.1% oxymetazoline solution (STN1013800) has been approved in Japan for the treatment of acquired ptosis, becoming the first non\u2011invasive therapy for the condition in the country. The approval marks a significant advancement in ptosis management, offering an alternative to surgical intervention for a broad patient population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53795#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53795\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53795#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Santen&#8217;s UPNEEQ Wins Japan Approval for Acquired Ptosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Santen's UPNEEQ Wins Japan Approval for Acquired Ptosis - Insight, China&#039;s Pharmaceutical Industry","description":"Santen Pharmaceutical Co., Ltd. announced that UPNEEQ Mini 0.1% oxymetazoline solution (STN1013800) has been approved in Japan for the treatment of acquired ptosis, becoming the first non\u2011invasive therapy for the condition in the country. The approval marks a significant advancement in ptosis management, offering an alternative to surgical intervention for a broad patient population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53795","og_locale":"en_US","og_type":"article","og_title":"Santen's UPNEEQ Wins Japan Approval for Acquired Ptosis","og_description":"Santen Pharmaceutical Co., Ltd. announced that UPNEEQ Mini 0.1% oxymetazoline solution (STN1013800) has been approved in Japan for the treatment of acquired ptosis, becoming the first non\u2011invasive therapy for the condition in the country. The approval marks a significant advancement in ptosis management, offering an alternative to surgical intervention for a broad patient population.","og_url":"https:\/\/flcube.com\/?p=53795","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T14:09:57+00:00","article_modified_time":"2026-01-12T14:09:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53795#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53795"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Santen&#8217;s UPNEEQ Wins Japan Approval for Acquired Ptosis","datePublished":"2026-01-12T14:09:57+00:00","dateModified":"2026-01-12T14:09:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53795"},"wordCount":443,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ophthalmology","Product approvals","Santen Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53795#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53795","url":"https:\/\/flcube.com\/?p=53795","name":"Santen's UPNEEQ Wins Japan Approval for Acquired Ptosis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-12T14:09:57+00:00","dateModified":"2026-01-12T14:09:58+00:00","description":"Santen Pharmaceutical Co., Ltd. announced that UPNEEQ Mini 0.1% oxymetazoline solution (STN1013800) has been approved in Japan for the treatment of acquired ptosis, becoming the first non\u2011invasive therapy for the condition in the country. The approval marks a significant advancement in ptosis management, offering an alternative to surgical intervention for a broad patient population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53795#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53795"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53795#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Santen&#8217;s UPNEEQ Wins Japan Approval for Acquired Ptosis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53795"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53795\/revisions"}],"predecessor-version":[{"id":53798,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53795\/revisions\/53798"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}